These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 2689951)
1. [Acetylator phenotype in spondylarthritis ankylopoietica]. Rojkovich B; Genti G; Borbás E; Bálint G; Gömör B Orv Hetil; 1989 Dec; 130(49):2639-41. PubMed ID: 2689951 [TBL] [Abstract][Full Text] [Related]
2. Hepatic acetylator phenotype in diabetes mellitus. Ladero JM; Arrojo A; de Salamanca RE; Gomez M; Cano F; Alfonso M Ann Clin Res; 1982 Aug; 14(4):187-9. PubMed ID: 7168549 [TBL] [Abstract][Full Text] [Related]
3. [Antitubercular agents: pharmacogenetic factors in the development of adverse effects]. Ligueros M; Saavedra H; Neira S; Cruz-Coke R; Saavedra A; Kramer V; Gelman M; Nuñez A; Prieto JC Rev Med Chil; 1990 Jul; 118(7):727-35. PubMed ID: 2131519 [TBL] [Abstract][Full Text] [Related]
4. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe. William BM; Abdel-tawab AM; Hassan EA; Mohamed OF Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499 [TBL] [Abstract][Full Text] [Related]
5. [Direct and indirect determination of an acetylator phenotype in patients during treatment with hydralazine]. McNair A; Kristensen MB; Angelo HR; Christensen JM Ugeskr Laeger; 1981 Jun; 143(27):1696-9. PubMed ID: 7292741 [No Abstract] [Full Text] [Related]
6. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report]. Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058 [TBL] [Abstract][Full Text] [Related]
7. [Distribution pattern of acetylator phenotypes: effect of age]. Gachályi B; Vas A; Hajös P; Káldor A Orv Hetil; 1984 Jan; 125(2):75-7. PubMed ID: 6694835 [No Abstract] [Full Text] [Related]
8. Caffeine as a potential indicator for acetylator status. Rankin RB; Hudson SA; Fell AF J Clin Pharm Ther; 1987 Feb; 12(1):47-51. PubMed ID: 3449563 [TBL] [Abstract][Full Text] [Related]
9. Determination of acetylator phenotype in Sri Lankans. Perera PL; Weerasinghe WM Ceylon Med J; 1987 Mar; 32(1):29-34. PubMed ID: 3690726 [No Abstract] [Full Text] [Related]
10. The influence of the acetylator phenotype for the clinical use of dihydralazine. Siegmund W; Franke G; Biebler KE; Donner I; Kallwellis R; Kairies M; Scherber A; Hüller H Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S74-8. PubMed ID: 3842694 [TBL] [Abstract][Full Text] [Related]
11. Hepatic acetylator phenotype in bladder cancer patients. Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447 [TBL] [Abstract][Full Text] [Related]
12. Drug acetylator phenotypes in newborn infants. Szórády I; Sánta A; Veress I Biol Res Pregnancy Perinatol; 1987; 8(1 1ST Half):23-5. PubMed ID: 3580445 [TBL] [Abstract][Full Text] [Related]
14. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. Frederickson SM; Messing EM; Reznikoff CA; Swaminathan S Cancer Epidemiol Biomarkers Prev; 1994; 3(1):25-32. PubMed ID: 8118381 [TBL] [Abstract][Full Text] [Related]
15. [Inactivation of drugs by acetylation]. Walstad RA Tidsskr Nor Laegeforen; 1975 Jan; 95(2):100-3. PubMed ID: 1114495 [No Abstract] [Full Text] [Related]